Digital biomarkers market seen reaching $23.02 billion by 2035

Market Research Future projects the global digital biomarkers market will grow from $4.18 billion in 2025 to $23.02 billion by 2035, driven by regulatory endpoint qualification, decentralized trials and broader reimbursement for remote monitoring. North America leads today, while Asia-Pacific is the fastest-growing region.

Why it matters: - Digital biomarkers are moving from experimental tools to regulated, reimbursable clinical evidence. - That shift could speed drug development, expand remote patient monitoring and make continuous health measurement more commercially viable. - The market’s projected growth reflects rising demand from drug makers, payers and providers for more frequent and more objective health data.

What happened: - Market Research Future projected the global digital biomarkers market will rise from $4.18 billion in 2025 to $23.02 billion by 2035. - The forecast implies an 18.6% compound annual growth rate from 2026 to 2035. - The report tied the growth outlook to regulatory qualification of sensor-derived endpoints, decentralized trial adoption and improving sensor and AI capabilities. - The report also identified North America as the largest regional market in 2025, with 41.5% of global revenue, or about $1.73 billion.

The details: - Regulatory acceptance is expanding for sensor-derived endpoints under FDA and EMA pathways. - Decentralized and hybrid clinical trials are increasing use of wearables, mobile health apps and remote monitoring systems. - Pharmaceutical sponsors spent about $2.4 billion on decentralized trial infrastructure in 2024. - Roughly 38% of Phase II and Phase III protocols included sensor-derived endpoints. - Photoplethysmography modules fell from about $12 in 2019 to below $4 at volume. - Transformer-based models achieved above 94% gait-event classification accuracy, according to the report. - CMS remote physiologic monitoring codes generated more than $1.1 billion in Medicare billings in 2024. - Germany’s DiGA fast-track has listed dozens of prescribable digital applications with statutory reimbursement. - France created an early-access reimbursement corridor through its PECAN scheme in 2024. - In the component segment, data collection tools held the largest share at 56% in 2025. - Data integration and analytics platforms were the fastest-growing component segment, with a 20.3% CAGR. - By data source, wearables led with 47% share in 2025. - Implantables were the fastest-growing data source, with a 21.7% CAGR. - Smartphones and mobile apps represented $1.00 billion of the market in 2025. - By therapeutic area, neurological disorders were the largest segment at $1.09 billion in 2025. - Oncology was the fastest-growing therapeutic area, with a 22.8% CAGR. - Cardiovascular disorders held 23% share in 2025. - By end user, pharmaceutical and biotech companies accounted for 36% of the market in 2025. - Payers were the fastest-growing end-user segment, with a 20.9% CAGR. - Healthcare providers represented $1.38 billion in 2025.

Between the lines: - The market is being shaped less by consumer wellness trends and more by clinical and reimbursement infrastructure. - Endpoint qualification and payer coverage are turning digital biomarkers into tools that can support trials, treatment decisions and population monitoring. - The market is still moderately fragmented, but a few large technology and medtech companies are setting much of the pace. - Philips, Medtronic and Apple are among the companies the report highlighted as major players. - Medtronic expanded its LINQ family analytics in September 2024 with AI-based arrhythmia classification, reducing false-positive alerts by more than 80%, according to the report. - Apple received clearance for a hypertension notification feature in September 2025.

What's next: - Market Research Future expects growth to continue through 2035 as more endpoints are qualified and more trials adopt continuous monitoring. - The report points to expansion in emerging markets, especially smartphone-first deployment models. - It also sees demand rising for predictive biomarkers, regulatory-grade software toolchains and endpoint standardization. - Asia-Pacific is projected to be the fastest-growing region at a 21.4% CAGR. - The Middle East and Africa market was about $0.17 billion in 2025 and is forecast to grow at 19.8% annually.

The bottom line: - Digital biomarkers are becoming part of the clinical evidence stack, and the next decade’s growth will hinge on whether regulation, reimbursement and trial design keep moving in the same direction.